Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Anti-interleukin-2 Receptor Antibodies—basiliximab and Daclizumab—for the Prevention of Acute Rejection in Renal Transplantation
暂无分享,去创建一个
[1] A. Webster,et al. Steroid avoidance or withdrawal for kidney transplant recipients. , 2016, The Cochrane database of systematic reviews.
[2] E. Woodle,et al. A Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial Comparing Early (7 Day) Corticosteroid Cessation Versus Long-Term, Low-Dose Corticosteroid Therapy , 2008, Annals of surgery.
[3] J. Gaynor,et al. Randomized Trial of Mycophenolate Mofetil Versus Enteric-Coated Mycophenolate Sodium in Primary Renal Transplant Recipients Given Tacrolimus and Daclizumab/Thymoglobulin: One Year Follow-Up , 2008, Transplantation.
[4] W. Meyers,et al. Long‐Term Outcome of Early Steroid Withdrawal After Kidney Transplantation in African American Recipients Monitored by Surveillance Biopsy , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[5] F. Schena,et al. A Randomized, Multicenter Study of Steroid Avoidance, Early Steroid Withdrawal or Standard Steroid Therapy in Kidney Transplant Recipients , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[6] P. Halloran,et al. Reduced exposure to calcineurin inhibitors in renal transplantation. , 2007, The New England journal of medicine.
[7] J. Gaynor,et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow‐up , 2007, Clinical transplantation.
[8] M. Salvadori,et al. A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[9] K. Salmela,et al. Single Bolus Antithymocyte Globulin Versus Basiliximab Induction in Kidney Transplantation With Cyclosporine Triple Immunosuppression: Efficacy and Safety , 2007, Transplantation.
[10] L. Rostaing,et al. Renal function with delayed or immediate cyclosporine microemulsion in combination with enteric‐coated mycophenolate sodium and steroids: results of follow up to 30 months post‐transplant , 2007, Clinical transplantation.
[11] A. Novick,et al. Kidney Transplantation With Sirolimus and Mycophenolate Mofetil–Based Immunosuppression: 5-Year Results of a Randomized Prospective Trial Compared to Calcineurin Inhibitor Drugs , 2007, Transplantation.
[12] A. Novick,et al. Kidney Transplantation With Sirolimus and Mycophenolate Mofetil–Based Immunosuppression: 5-Year Results of a Randomized Prospective Trial Compared to Calcineurin Inhibitor Drugs , 2007 .
[13] B. Nashan,et al. Cyclosporine Sparing with Mycophenolate Mofetil, Daclizumab and Corticosteroids in Renal Allograft Recipients: The CAESAR Study , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[14] J. Pascual,et al. 12‐month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients , 2007, Transplant international : official journal of the European Society for Organ Transplantation.
[15] D. Brennan,et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. , 2006, The New England journal of medicine.
[16] B. Dimitrov,et al. Long‐Term Renal Allograft Function on a Tacrolimus‐Based, Pred‐Free Maintenance Immunosuppression Comparing Sirolimus vs. MMF † , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[17] Minzhuan Lin,et al. Two‐dose basiliximab compared with two‐dose daclizumab in renal transplantation: a clinical study , 2006, Clinical transplantation.
[18] L. Rostaing,et al. Impact of Early or Delayed Cyclosporine on Delayed Graft Function in Renal Transplant Recipients: A Randomized, Multicenter Study , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[19] M. Moritz,et al. Safety and Efficacy of Steroid Withdrawal Two Days after Kidney Transplantation: Analysis of Results at Three Years , 2006, Transplantation.
[20] J. Squifflet,et al. Two Corticosteroid-Free Regimens—Tacrolimus Monotherapy after Basiliximab Administration and Tacrolimus/Mycophenolate Mofetil—in Comparison with a Standard Triple Regimen in Renal Transplantation: Results of the Atlas Study , 2005, Transplantation.
[21] V. Dharnidharka. Costimulation blockade with belatacept in renal transplantation. , 2005, The New England journal of medicine.
[22] D. Axelrod,et al. Alemtuzumab Induction and Prednisone‐Free Maintenance Immunotherapy in Kidney Transplantation: Comparison with Basiliximab Induction—Long‐Term Results , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[23] M. Moritz,et al. Comparison of Steroid Avoidance in Tacrolimus/Mycophenolate Mofetil and Tacrolimus/Sirolimus Combination in Kidney Transplantation Monitored by Surveillance Biopsy , 2005, Transplantation.
[24] J. Gaynor,et al. A Randomized Trial of Three Renal Transplant Induction Antibodies: Early Comparison of Tacrolimus, Mycophenolate Mofetil, and Steroid Dosing, and Newer Immune-Monitoring1 , 2005, Transplantation.
[25] M. Moritz,et al. Avoidance of Chronic Steroid Therapy in African American Kidney Transplant Recipients Monitored by Surveillance Biopsy: 1‐Year Results , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[26] K. Budde,et al. Corticosteroid-Free Immunosuppression with Tacrolimus, Mycophenolate Mofetil, and Daclizumab Induction in Renal Transplantation , 2005, Transplantation.
[27] J. Alexander,et al. A prospective, pilot study of early corticosteroid cessation in high-immunologic-risk patients: the Cincinnati experience. , 2005, Transplantation proceedings.
[28] C. Watson,et al. Multicenter, Randomized Study of the Effectiveness of Basiliximab in Avoiding Addition of Steroids to Cyclosporine A Monotherapy in Renal Transplant Recipients , 2005, Transplantation.
[29] H. Gritsch,et al. A Multicenter Pilot Study of Early (4‐Day) Steroid Cessation in Renal Transplant Recipients Under Simulect, Tacrolimus and Sirolimus , 2005, American Journal of Transplantation.
[30] L. Truong,et al. A Truncated-Dose Regimen of Daclizumab for Prevention of Acute Rejection in Kidney Transplant Recipients: A Single-Center Experience , 2004, Transplantation.
[31] J. Pascual,et al. Steroid Withdrawal in Renal Transplant Patients on Triple Therapy with a Calcineurin Inhibitor and Mycophenolate Mofetil: A Meta-analysis of Randomized, Controlled Trials , 2004, Transplantation.
[32] C. Ponticelli,et al. Everolimus and Reduced-Exposure Cyclosporine in de novo Renal-Transplant Recipients: A Three-Year Phase II, Randomized, Multicenter, Open-Label Study , 2004, Transplantation.
[33] S. Head,et al. De Novo Kidney Transplantation Without Use of Calcineurin Inhibitors Preserves Renal Structure and Function at Two Years , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[34] L. Rostaing,et al. Sequential Protocols using Basiliximab versus Anti-Thymocyte Globulins in Renal-Transplant Patients Receiving Mycophenolate Mofetil and Steroids , 2004, Transplantation.
[35] J. Chapman,et al. Calcineurin Inhibitor Nephrotoxicity: Longitudinal Assessment by Protocol Histology , 2004, Transplantation.
[36] R. Stratta,et al. One-year outcomes in simultaneous kidney-pancreas transplant recipients receiving an alternative dosing regimen of daclizumab. , 2004, Transplantation proceedings.
[37] G. Borm,et al. Steroid‐Withdrawal at 3 Days After Renal Transplantation with Anti‐IL‐2 Receptor α Therapy: A Prospective, Randomized, Multicenter Study , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[38] Julio Pascual,et al. Everolimus with Optimized Cyclosporine Dosing in Renal Transplant Recipients: 6‐Month Safety and Efficacy Results of Two Randomized Studies , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[39] G. Ciancio,et al. The use of daclizumab as induction therapy in combination with tacrolimus and mycophenolate mofetil in recipients with previous transplants , 2003, Clinical transplantation.
[40] O. Pankewycz,et al. Basiliximab plus low‐dose cyclosporin vs. OKT3 for induction immunosuppression following renal transplantation , 2003, Clinical transplantation.
[41] G. Ciancio,et al. The Use of Daclizumab, Tacrolimus and Mycophenolate Mofetil in African‐American and Hispanic First Renal Transplant Recipients , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[42] W. Almawi,et al. Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation. , 2003, Molecular immunology.
[43] D. Adu,et al. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials , 2003, BMJ : British Medical Journal.
[44] P. Bacchetti,et al. Sirolimus Prolongs Recovery from Delayed Graft Function After Cadaveric Renal Transplantation , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[45] G. Ciancio,et al. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression. , 2003, Transplantation proceedings.
[46] A. Monaco,et al. Multicenter Randomized Prospective Trial of Steroid Withdrawal in Renal Transplant Recipients Receiving Basiliximab, Cyclosporine Microemulsion and Mycophenolate Mofetil , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[47] L. Rostaing,et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. , 2003, Transplantation.
[48] F. Vincenti,et al. Pharmacokinetic and Pharmacodynamic Studies of One or Two Doses of Daclizumab in Renal Transplantation , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[49] J. Kovarik,et al. A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations1 , 2002, Transplantation.
[50] E. Benedetti,et al. Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients. , 2002, Transplantation proceedings.
[51] G. Ciancio,et al. Effect of daclizumab, tacrolimus and mycophenolate mofetil in racial minority first renal transplant recipients. , 2002, Transplantation proceedings.
[52] G. Ciancio,et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients1 , 2002, Transplantation.
[53] O. Toupance,et al. Immunoprophylaxis with Basiliximab Compared with Antithymocyte Globulin in Renal Transplant Patients Receiving MMF‐containing Triple Therapy , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[54] F. Citterio. Steroid side effects and their impact on transplantation outcome. , 2001, Transplantation.
[55] M. Pescovitz,et al. BASILIXIMAB VERSUS ANTITHYMOCYTE GLOBULIN FOR PREVENTION OF ACUTE RENAL ALLOGRAFT REJECTION1,2 , 2001, Transplantation.
[56] A. Hoitsma,et al. Two doses of daclizumab are sufficient for prolonged interleukin-2Ralpha chain blockade. , 2001, Transplantation.
[57] H. Theodoropoulou,et al. Monoclonal antibody basiliximab with low cyclosporine dose as initial immunosuppression. , 2001, Transplantation proceedings.
[58] R. Lechler,et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. , 2001, Transplantation.
[59] M. Pescovitz,et al. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. , 2001, Transplantation.
[60] B. Kiberd,et al. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. , 2001, Transplantation.
[61] K. Johny,et al. Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients. , 2001 .
[62] B. Nashan,et al. MULTICENTER TRIAL EXPLORING CALCINEURIN INHIBITORS AVOIDANCE IN RENAL TRANSPLANTATION , 2001, Transplantation.
[63] Johnny C. Hong,et al. A CALCINEURIN ANTAGONIST-FREE INDUCTION STRATEGY FOR IMMUNOSUPPRESSION IN CADAVERIC KIDNEY TRANSPLANT RECIPIENTS AT RISK FOR DELAYED GRAFT FUNCTION1 , 2001, Transplantation.
[64] J. Kovarik,et al. Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients , 2001, Clinical transplantation.
[65] O. Pankewycz,et al. Induction strategy using basiliximab combined with mycophenolate MMF and immediate low-dose cyclosporin is steroid sparing and more effective than OKT3. , 2001, Transplantation proceedings.
[66] G. Iaria,et al. Preliminary results of a prospective randomized study of basiliximab in kidney transplantation. , 2001, Transplantation proceedings.
[67] A. Miller,et al. Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression. , 2001, Transplantation proceedings.
[68] J. Roberts,et al. A calcineurin inhibitor‐sparing regimen with sirolimus, mycophenolate mofetil, and anti‐CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function , 2000, Clinical transplantation.
[69] F. Oppenheimer,et al. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. , 2000, Transplantation.
[70] L. Pape,et al. Interleukin-2 receptor antibodyinduced alterations of ciclosporin dose requirements in paediatric transplant recipients , 2000, The Lancet.
[71] H. Auchincloss,et al. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. , 2000, Journal of the American Society of Nephrology : JASN.
[72] S. Mulgaonkar,et al. The effect of Daclizumab in a high‐risk renal transplant population , 2000, Clinical transplantation.
[73] F. Wright,et al. Daclizumab in live donor renal transplantation. , 2000, Transplantation proceedings.
[74] S. Mulgaonkar,et al. Efficacy of Daclizumab in an African-American and Hispanic renal transplant population , 2000, Transplant International.
[75] F. Vincenti,et al. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis , 2000, Transplant international : official journal of the European Society for Organ Transplantation.
[76] D. Stablein,et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil--a prospective randomized study. Steroid Withdrawal Study Group. , 1999, Transplantation.
[77] G. Becker,et al. Impact of acute rejection therapy on infections and malignancies in renal transplant recipients. , 1999, Transplantation.
[78] F. Vincenti. Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation. , 1999, Transplantation proceedings.
[79] M. Hall,et al. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. , 1999, Transplantation.
[80] B. Nashan,et al. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. , 1999, Transplantation.
[81] J. Thistlethwaite,et al. Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group. , 1998, Transplantation.
[82] J. Kovarik,et al. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. , 1997, Transplantation.
[83] J. Soulillou,et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients , 1997, The Lancet.
[84] D. Mould,et al. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. , 1997, Transplantation.
[85] M. Schreier,et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. , 1995, Transplantation.
[86] W. Payne,et al. THE IMPACT OF AN ACUTE REJECTION EPISODE ON LONG‐TERM RENAL ALLOGRAFT SURVIVAL (t1/2)1,2 , 1994, Transplantation.
[87] D. Dunn,et al. Risk factors for chronic rejection in renal allograft recipients. , 1993, Transplantation.
[88] T. Waldmann,et al. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. , 1991, Transplantation.
[89] P. Friend,et al. DELAYED ALLOGRAFT REJECTION IN PRIMATES TREATED WITH ANTI‐IL-2 RECEPTOR MONOCLONAL ANTIBODY CAMPATH‐6 , 1988, Transplantation.
[90] R. Marcén,et al. A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function , 2009, Clinical transplantation.
[91] Joan W. Miller,et al. Long-Term Results of Rabbit Antithymocyte Globulin and Basiliximab Induction , 2008 .
[92] D. Leehey,et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. , 2000, The New England journal of medicine.
[93] J. Kovarik,et al. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group. , 1999, Transplantation.
[94] J Neylan,et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. , 1998, The New England journal of medicine.
[95] N. Sinclair,et al. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[96] T. Waldmann,et al. Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody. , 1989, Transplantation.